EIF3M

Eukaryotic translation initiation factor 3 subunit M · Q7L2H7 · EIF3M on Sugi Atlas →

0 patent compounds predicted against EIF3M, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EIF3M by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients nanSUSPENDED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF3M binder may also engage these)

ProteinNameSimilarity
Q5R8C4 1.000 Q5R8C4 →
Q5ZJ64 1.000 Q5ZJ64 →
Q7T3B0 1.000 Q7T3B0 →
Q6DK91 1.000 Q6DK91 →
Q99JX4 1.000 Q99JX4 →
Q3T148 0.999 Q3T148 →
Q7ZYU8 0.996 Q7ZYU8 →
Q7Q068 0.995 Q7Q068 →
Q17D30 0.994 Q17D30 →
B3MCZ5 0.989 B3MCZ5 →
B4LJT9 0.988 B4LJT9 →
Q292F0 0.988 Q292F0 →
Q7JVI3 0.988 Q7JVI3 →
B0WTN3 0.988 B0WTN3 →
B3NRC6 0.987 B3NRC6 →
B4JW83 0.987 B4JW83 →
B4KT65 0.987 B4KT65 →
B4GDM5 0.987 B4GDM5 →
B4MY75 0.986 B4MY75 →
B4QFD2 0.986 B4QFD2 →
B4HR14 0.986 B4HR14 →
B4P6M6 0.985 B4P6M6 →
Q9C5Z3 0.981 Q9C5Z3 →
Q9I8E6 0.981 Q9I8E6 →
A7RWP6 0.981 A7RWP6 →
Q0CNR3 0.981 Q0CNR3 →
F4IDS7 0.980 F4IDS7 →
Q9QZE5 0.980 Q9QZE5 →
Q6P3X3 0.980 Q6P3X3 →
Q9PUE4 0.980 Q9PUE4 →